,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2021', 'fs': 'Jul 2021', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006IiR5UAK'}, 'Id': 'a0P2P000006IiR5UAK', 'Event_Date__c': '2021-07-07', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jul 2021', 'Status_History__c': 'a132P000000D0c7QAC'}, 'change': None}]",Jul 2021,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2021', 'fs': 'Jul 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006IiR6UAK'}, 'Id': 'a0P2P000006IiR6UAK', 'Event_Date__c': '2021-07-13', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2021', 'Status_History__c': 'a132P000000D0cCQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2022', 'fs': 'Jan 2022', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 17 February 2022', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 17 February 2022', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006IiR7UAK'}, 'Id': 'a0P2P000006IiR7UAK', 'Event_Date__c': '2022-01-28', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 17 February 2022', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jan 2022', 'Status_History__c': 'a132P000000DUwfQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that palivizumab be funded for the next two RSV seasons (2022/2023), with a view to reviewing funding and eligibility criteria following the 2023 RSV season (i.e. at two years after this recommendation), for RSV prophylaxis of children under the age of 12 months who are at high risk of developing RSV disease, with a <b>high priority</b>, subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><b style=""font-size: 11px; color: rgb(51, 51, 51);"">PALIVIZUMAB – RSV PROPHYLAXIS FOR THE 2022/2023 RSV SEASONS, IN THE CONTEXT OF COVID-19</b></p><p class=""ql-indent-1""><b style=""font-size: 11px; color: rgb(51, 51, 51);"">Initial application </b><span style=""font-size: 11px; color: rgb(51, 51, 51);"">only from a paediatrician. Approvals valid for 6 months.</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">1.\xa0\xa0\xa0\xa0Infant was born in the last 12 months; and</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.\xa0\xa0\xa0\xa0Any of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.1. Patient was born at less than 28 weeks gestation; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2. Both:</span></p><p class=""ql-indent-2""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2.1. Patient was born at less than 32 weeks gestation; and</span></p><p class=""ql-indent-2""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2.2. Either: </span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2.2.1. Patient has chronic lung disease; or</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2.2.2. Patient is Māori or any Pacific ethnicity; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3. Both:</span></p><p class=""ql-indent-2""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.1. Patient has haemodynamically significant heart disease; and</span></p><p class=""ql-indent-2""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2. Any of the following:</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2.1. Patient has unoperated simple congenital heart disease with significant left to right shunt (see note a); or</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2.2. Patient has unoperated or surgically palliated complex congenital heart disease; or</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2.3. Patient has severe pulmonary hypertension (see note b); or</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2.4. Patient has moderate or severe LV failure (see note c)</span></p><p><span style=""font-size: 11px;"">\t</span><b style=""font-size: 11px; color: rgb(51, 51, 51);"">Note</b><span style=""font-size: 11px; color: rgb(51, 51, 51);"">:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">a)\xa0\xa0\xa0\xa0Patient requires/will require heart failure medication, and/or patient has significant pulmonary hypertension, and/or patient will require surgical palliation/definitive repair within the next 3 months</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">b)\xa0\xa0\xa0\xa0Mean pulmonary artery pressure more than 45 mmHg</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">c)\xa0\xa0\xa0\xa0LV Ejection Fraction less than 40%</span></p><p class=""ql-indent-1""><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee considered that:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>RSV significantly and disproportionately impacts premature infants who are Māori, Pacific, or living in areas with low socio-economic status (deprivation index 8-10) in their first year of life</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The seasonal characteristics of RSV are highly uncertain in the next two years in the context of the COVID-19 pandemic and an atypical season with greater impact than normal RSV seasons cannot be ruled out</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence for palivizumab prophylaxis in this population supports a reduction in hospitalisation in the target population who are vulnerable and already require a high level of health system engagement and support</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In the context of the COVID-19 pandemic, reducing hospitalisations in this target population would be associated with benefits to the health system, given the expected burdens on DHB hospitals and ICUs</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence for other potential benefits (eg reductions in mortality or respiratory sequelae) from palivizumab is of poor quality and weak strength therefore other benefits to individuals remain unquantified</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Equitable and effective implementation of palivizumab prophylaxis will require substantial engagement with the relevant clinical teams and community health providers, and resolution of important logistical challenges regarding its distribution.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac should inform the Respiratory Advisory Committee and the Immunisation Advisory Committee of the Committee’s recommendation to fund palivizumab prophylaxis for the target population for the next two RSV seasons and suggested staff seek advice from these Advisory Committees about how palivizumab access could be effectively and equitably implemented.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac could seek advice from relevant clinical teams [eg neonatal intensive care units (NICU), cardiology and respiratory teams, infectious diseases] and community health providers (eg Māori health providers, GPs and rural health providers) to establish an appropriate distribution and implementation approach for the provision of palivizumab prophylaxis for the next two RSV seasons.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that palivizumab be funded for the next two RSV seasons (2022/2023), with a view to reviewing funding and eligibility criteria following the 2023 RSV season (i.e. at two years after this recommendation), for RSV prophylaxis of children under the age of 12 months who are at high risk of developing RSV disease, with a <b>high priority</b>, subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><b style=""font-size: 11px; color: rgb(51, 51, 51);"">PALIVIZUMAB – RSV PROPHYLAXIS FOR THE 2022/2023 RSV SEASONS, IN THE CONTEXT OF COVID-19</b></p><p class=""ql-indent-1""><b style=""font-size: 11px; color: rgb(51, 51, 51);"">Initial application </b><span style=""font-size: 11px; color: rgb(51, 51, 51);"">only from a paediatrician. Approvals valid for 6 months.</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">1.\xa0\xa0\xa0\xa0Infant was born in the last 12 months; and</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.\xa0\xa0\xa0\xa0Any of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.1. Patient was born at less than 28 weeks gestation; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2. Both:</span></p><p class=""ql-indent-2""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2.1. Patient was born at less than 32 weeks gestation; and</span></p><p class=""ql-indent-2""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2.2. Either: </span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2.2.1. Patient has chronic lung disease; or</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2.2.2. Patient is Māori or any Pacific ethnicity; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3. Both:</span></p><p class=""ql-indent-2""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.1. Patient has haemodynamically significant heart disease; and</span></p><p class=""ql-indent-2""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2. Any of the following:</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2.1. Patient has unoperated simple congenital heart disease with significant left to right shunt (see note a); or</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2.2. Patient has unoperated or surgically palliated complex congenital heart disease; or</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2.3. Patient has severe pulmonary hypertension (see note b); or</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2.4. Patient has moderate or severe LV failure (see note c)</span></p><p><span style=""font-size: 11px;"">\t</span><b style=""font-size: 11px; color: rgb(51, 51, 51);"">Note</b><span style=""font-size: 11px; color: rgb(51, 51, 51);"">:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">a)\xa0\xa0\xa0\xa0Patient requires/will require heart failure medication, and/or patient has significant pulmonary hypertension, and/or patient will require surgical palliation/definitive repair within the next 3 months</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">b)\xa0\xa0\xa0\xa0Mean pulmonary artery pressure more than 45 mmHg</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">c)\xa0\xa0\xa0\xa0LV Ejection Fraction less than 40%</span></p><p class=""ql-indent-1""><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee considered that:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>RSV significantly and disproportionately impacts premature infants who are Māori, Pacific, or living in areas with low socio-economic status (deprivation index 8-10) in their first year of life</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The seasonal characteristics of RSV are highly uncertain in the next two years in the context of the COVID-19 pandemic and an atypical season with greater impact than normal RSV seasons cannot be ruled out</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence for palivizumab prophylaxis in this population supports a reduction in hospitalisation in the target population who are vulnerable and already require a high level of health system engagement and support</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In the context of the COVID-19 pandemic, reducing hospitalisations in this target population would be associated with benefits to the health system, given the expected burdens on DHB hospitals and ICUs</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence for other potential benefits (eg reductions in mortality or respiratory sequelae) from palivizumab is of poor quality and weak strength therefore other benefits to individuals remain unquantified</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Equitable and effective implementation of palivizumab prophylaxis will require substantial engagement with the relevant clinical teams and community health providers, and resolution of important logistical challenges regarding its distribution.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac should inform the Respiratory Advisory Committee and the Immunisation Advisory Committee of the Committee’s recommendation to fund palivizumab prophylaxis for the target population for the next two RSV seasons and suggested staff seek advice from these Advisory Committees about how palivizumab access could be effectively and equitably implemented.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac could seek advice from relevant clinical teams [eg neonatal intensive care units (NICU), cardiology and respiratory teams, infectious diseases] and community health providers (eg Māori health providers, GPs and rural health providers) to establish an appropriate distribution and implementation approach for the provision of palivizumab prophylaxis for the next two RSV seasons.</p>', 'change': None}, 'Published_Discussion': {'s': '<h2><b style=""font-size: 11px;""><i>Māori impact</i></b></h2><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that respiratory disease inequitably impacts Māori and is one of Pharmac’s Hauora Arotahi (Māori health areas of focus). The Committee noted that RSV-related illness and hospitalisation significantly and disproportionately impacts premature Māori infants in their first year of life, who experience a higher rate of RSV-related hospitalisation compared with European and other (non-Pacific) ethnicities. The Committee noted that Māori infants have a greater relative risk of pre-term birth compared with European infants, and that Māori infants with <span style=""color: rgb(8, 7, 7);"">certain severe congenital heart defects have lower rates of surgical intervention and survival compared with European infants</span>. The Committee considered it important, especially given the disproportionate risk of prematurity and impact of congenital heart defects for Māori, to avoid disrupting care of premature infants already in hospital (especially those with cardiac disease), to better manage the extra care required for at-risk groups of infants, and to prevent and control intra-hospital infection. The Committee noted that the key outcome of benefit from palivizumab was a reduction in hospitalisation and considered that Special Authority criteria for palivizumab should specifically target Māori infants. However, the Committee noted that palivizumab would not address the disproportionate and inequitable impact of RSV on Māori infants. The Committee considered that equitable implementation of palivizumab for RSV prophylaxis would require proactive engagement with relevant parties including Māori healthcare providers and rural healthcare providers, noting that a range of challenges and barriers exist.</p><h2><b style=""font-size: 11px;""><i>Background</i></b></h2><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that an <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008pu58/p000585"" target=""_blank"">application for palivizumab for prevention of serious lower respiratory tract infections (LRTIs) caused by RSV in high-risk infants</a> was reviewed by PTAC and recommended for decline by PTAC at its February 2000, November 2000 meetings. It was formally declined in 2005 by the Pharmac Board.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2009-02.pdf"" target=""_blank"">February 2009</a>, PTAC reviewed a clinician request to allow for a pre-approved Hospital Exceptional Circumstances (HEC) system to allow patients at risk of RSV [infants under 2 years of age with severe chronic lung disease (CLD), with supplemental home oxygen requirements, or in the hospital preparing for discharge with the strong expectation of home oxygen] to access palivizumab. At that time, PTAC recommended it be declined due to the lack of strength and quality of the evidence and poor cost-effectiveness.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in July 2021, in response to the urgent need arising from a major increase in circulating RSV following the COVID-19 lockdown, Pharmac authorised DHBs to purchase palivizumab outside of the Pharmaceutical Schedule for high-risk patients that met certain criteria during the 2021 RSV outbreak. The target population was restricted to manage supply issues at the time whilst enabling access for high-risk patients. In <a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-09-20-palivizumab/"" target=""_blank"">September 2021</a>, Pharmac authorised widening of access for the 2021 RSV season to the intended, limited high-risk patient population.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pharmac received a funding application for palivizumab for RSV prophylaxis from a clinician in July 2021 and was seeking the Committee’s advice on this application in the context of the COVID-19 pandemic.</p><h2><b style=""font-size: 11px;""><i>Discussion</i></b></h2><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that RSV is the dominant respiratory virus accounting in New Zealand for about half of all cases of bronchiolitis, an acute respiratory infection, in infants and young children (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805750/"" target=""_blank"">Prasad et al. Epidemiol Infect. 2019; 147: e246</a>; <a href=""https://publications.aap.org/pediatrics/article-lookup/doi/10.1542/peds.2018-2308"" target=""_blank"">Alansari et al. Pediatrics. 2019;143:e20182308</a>). The Committee noted that RSV infects a large proportion of children who are less than one year of age, including many under three months or six months of age, and considered this was important, given the exponential lung development that occurs in the first year of life. The Committee noted that RSV cases present with symptoms of respiratory distress (predominantly wheeze), that the virus affects more boys than girls, and that RSV-related illness is treated with supportive care.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that RSV disproportionately impacts indigenous populations worldwide. Respiratory disease is known to have an inequitable impact on Māori and is one of Pharmac’s <a href=""https://pharmac.govt.nz/te-tiriti-o-waitangi/hauora-arotahi-maori-health-areas-of-focus/"" target=""_blank"">Hauora Arotahi</a><span style=""color: rgb(51, 51, 51);""> </span>(Māori health areas of focus). The Committee noted that RSV-related illness and hospitalisation disproportionately impacts premature Māori infants in their first year of life<span style=""color: black;"">.</span> The Committee noted that RSV-related <span style=""color: black;"">hospitalisation was higher in Māori children [rate ratio (RR) 4.0, 95% CI: 3.4 to 4.7] compared with European or other ethnicities </span><span style=""color: rgb(33, 33, 33);"">(</span><a href=""https://doi.org/10.1097/INF.0000000000002681"" target=""_blank"">Prasad et al. Pediatr Infect Dis J. 2020;39:e176-e182</a><span style=""color: rgb(33, 33, 33);"">). </span><span style=""color: black;"">The Committee was made aware of evidence of infants admitted to a New Zealand paediatric intensive care unit with bronchiolitis from 1991 to 1994; members considered this suggested that Māori infants with RSV are disproportionally represented in these admissions. Members noted however that there was no difference based on ethnicity for patients who required respiratory support (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/8649668/"" target=""_blank"">Gavin et al. N Z Med J. 1996;109:137-9</a><span style=""color: rgb(33, 33, 33);"">). </span>The Committee noted that <span style=""color: rgb(8, 7, 7);"">Māori women had a greater relative risk of having extremely or very preterm infants than European women, and that the relative risk of neonatal death or post-neonatal death was higher in Māori women than European women (</span><a href=""https://doi.org/10.1002/ijgo.13855"" target=""_blank"">Edmonds et al. Int J Gynaecol Obstet. 2021;155:239-46</a><span style=""color: rgb(8, 7, 7);"">). The Committee noted that, although Māori infants may not have higher rates of CHD than non-Māori, there is evidence that Māori infants with certain severe congenital heart defects have lower rates of surgical intervention and lower survival rates compared with European infants (</span><a href=""https://adc.bmj.com/lookup/pmidlookup?view=long&amp;pmid=30824490"" target=""_blank"">Cloete et al. Arch Dis Child. 2019;104:857-62</a><span style=""color: rgb(8, 7, 7);"">). </span></p><p><span style=""font-size: 12px;"">1.8</span><i style=""font-size: 12px;"">.</i><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that RSV also disproportionately impacts premature Pacific infants in their first year of life. The rate of RSV-related <span style=""color: black;"">hospitalisation was also higher in Pacific children (RR 2.9, 95% CI: 2.5 to 3.4) compared with European or other ethnicities </span><span style=""color: rgb(33, 33, 33);"">(</span><a href=""https://doi.org/10.1097/INF.0000000000002681"" target=""_blank"">Prasad et al. 2020</a><span style=""color: rgb(33, 33, 33);"">)</span><span style=""color: black;"">. </span>Members noted that, like Māori infants, Pacific infants and Indian infants are overrepresented in the incidence of pre-term births <span style=""color: rgb(8, 7, 7);"">(</span><a href=""https://doi.org/10.1002/ijgo.13855"" target=""_blank"">Edmonds et al. 2021)</a>. <span style=""color: rgb(33, 33, 33);"">The </span><span style=""color: black;"">Committee </span>noted that no New Zealand-specific data were available for the rates of RSV-related hospitalisation in Indian infants. The Committee noted that living in an area of low <span style=""color: black;"">socio-economic status\xa0(SES) (deprivation index 8 to 10) </span>independently increased the risk of an RSV-associated hospitalisation in children<span style=""font-size: 10pt;""> </span>(RR 1.3, 95% CI 1.0 to 1.6) <span style=""color: rgb(33, 33, 33);"">(</span><a href=""https://doi.org/10.1097/INF.0000000000002681"" target=""_blank"">Prasad et al. 2020</a><span style=""color: rgb(33, 33, 33);"">)</span>. Given the evidenced increase in risk of RSV-associated hospitalisation for infants in areas of high deprivation, the Committee considered it could be appropriate to target these infants for funded treatment.<span style=""color: rgb(33, 33, 33);""> </span></p><p><span style=""font-size: 12px;"">1.9</span><i style=""font-size: 12px;"">.</i><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that premature infants, infants with lung disease, and infants with CHD are the patient groups most at risk of RSV-related hospitalisation. Members noted there is ongoing debate regarding whether infants who are immunocompromised, have neuromuscular disorders, have trisomy 21, or require long-term ventilation have the same elevated risk of RSV-related hospitalisation.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that hospitalisation itself adversely affects normal family/whānau functioning and that hospitalisation for RSV further impacts family/whānau where children are usually transferred to large treatment centres (eg Auckland’s Starship Hospital) for care. The Committee noted the family/whānau impact of hospitalisation for RSV was reported in a study of caregivers of pre-term US infants hospitalised with RSV, who experienced stress, poor health and productivity loss at discharge, and were emotionally impacted, had disruption of family routine, financial concerns and medical concerns continue after discharge (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31007050/"" target=""_blank"">Pokrzywinski et al. Clin Pediatr (Phila). 2019;58:837-50</a>).</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that RSV typically circulates annually in the winter season from May to October in New Zealand and that in Auckland, laboratory-confirmed RSV cases peak at about 50 cases per week, contributing substantially to the number of hospitalisations for acute bronchiolitis (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805750/"" target=""_blank"">Prasad et al. 2019</a>). The Committee noted that the authors of this Auckland-based study reported that half of RSV-related hospitalisations were in children under six months and that that hospitalisation due to RSV was 30 times as likely in children less than three months of age compared with children aged two to five years. The Committee noted that from 2012 to 2015, 5,309 overnight hospitalisations (median 2 days duration) were reported for acute respiratory infection among children aged under five years, with 433 (8.2%) admitted to intensive care units (ICU). The Committee considered that this reflected the substantial health resource needed to care for young children hospitalised with RSV and the high rate of paediatric ICU (PICU) admissions that result. However, the Committee considered that further health resources are required for infection prevention and control measures, as RSV can spread rapidly within hospitals, and noted that unwell infants including those at high risk of RSV-related hospitalisation already require substantial care and engagement with neonatal facilities in hospital.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that mortality from RSV is low in New Zealand, noting a recent study reported the rate of death among RSV-positive children was 0.18% (n=3), compared with the rate of all-cause mortality among all patients admitted overnight for acute respiratory infection (0.4%, n=19) (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805750/"" target=""_blank"">Prasad et al. 2019</a>). However, the Committee noted that some infants hospitalised with RSV are assumed to experience an increased risk of death, ranging from 3.72% to 4% for CHD and CLD patients, respectively, and 0.43% for premature babies (less than 32 weeks gestational age) without CHD and CLD (<a href=""https://pubmed.ncbi.nlm.nih.gov/19049692/"" target=""_blank"">Wang et al, Health Technol Assess. 2008</a>). The Committee noted the evidence for a reduction in mortality following hospitalisation in infants hospitalised for RSV who received palivizumab compared with those who received placebo, no intervention, or standard care (two-year all-cause mortality relative risk [RR] 0.69, 95% CI 0.42 to 1.15; <a href=""https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013757.pub2/full"" target=""_blank"">Garegnani et al. Cochrane Database Syst Rev. 2021;11(11):CD013757</a>). The Committee was made aware of weak evidence for hospital mortality of children with congenital heart disease up to 12 months of age (0.56% in 2012 to 2014 vs 1.93% in 2014 to 2016, <i>P</i> = 0.051; <a href=""http://hdl.handle.net/2027.42/144272"" target=""_blank"">Walpert et al. Congenit Heart Dis. 2018;13:428-31</a>). Members considered that hospitalisation in PICU may be associated with increased all-cause mortality and that bronchiolitis could contribute to overall mortality. On balance, the Committee considered the difference in the mortality risk for hospitalised infants with RSV compared with infants in the community with RSV was very low.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that a very small minority of infants and children can have virus-associated encephalopathy and cardiomyopathy and some may have mild respiratory damage after RSV infection, lasting three to four months. Members considered that two or three children with RSV per year (especially those with pre-existing lung pathology) develop long-term lung pathology from ventilation treatment. The Committee considered that ongoing effects such as wheeze, subsequent bronchiolitis, and an increased risk of RSV infection generally last up to one year and would not require significant intervention or treatment. The Committee considered that the association between RSV infection and asthma post-RSV was uncertain and that a possible link was likely to be complicated by other factors.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the public health measures, border closures and restrictions used in response to the COVID-19 pandemic resulted in a lack of circulating RSV and no noteworthy 2020 RSV season. The Committee noted that alleviation of these measures and the lack of previous exposure to RSV for infants led to a larger and longer atypical 2021 season of RSV circulation which peaked at about 1,000 laboratory-confirmed RSV cases per week in Auckland (compared to previous peak of about 50 cases per week). The Committee noted that 2021 season put enormous pressure on secondary care, impacting on hospitals and ICU beds, caused staff and family sickness, led to elective surgery cancellations and intra-hospital spread. The Committee noted that primary care including GP and nurse teams managed the vast majority of RSV cases in 2021 which impacted the ability of primary care to provide usual care (eg resulting in deferral of routine smears and diabetes reviews).</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the COVID-19 response applies similar pressures to both primary and secondary care services, with limited capacity for ICU care of infants with RSV requiring hospitalisation. The Committee considered that an increase in morbidity and mortality in some populations would be expected if an RSV season overlapped with COVID-19 circulation (eg leading to dual RSV and COVID-19 infections in critically ill inpatients) and that premature infants may be at greater risk if hospitals are at capacity treating COVID-19 cases. The Committee considered that future RSV seasonality is uncertain but, given the atypical RSV seasons overseas, that it was possible New Zealand would also experience an atypical future season or out-of-season surge with greater impact than typical RSV seasons. The Committee considered that significant health system resource would be needed to manage an atypical RSV season in the context of the COVID-19 pandemic response and that reducing hospitalisation was a key area of need for the health system.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that palivizumab is a humanised IgG1 monoclonal antibody that is Medsafe- approved for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease. The Committee noted that palivizumab is administered in a dose of 15 mg/kg intramuscularly and should be given monthly during anticipated periods of RSV risk in the community. The Committee noted that palivizumab has been recommended for RSV prophylaxis in some international jurisdictions (eg UK, Canada, Australia), in paediatric clinical guidelines (eg UK and USA) and considered that the jurisdictions reporting better cost-effectiveness with palivizumab had targeted access to populations most at risk of RSV-related hospitalisation. The Committee noted that palivizumab had recently been recommended for at-risk preterm infants in the context of COVID-19 by <a href=""https://www.england.nhs.uk/wp-content/uploads/2020/10/C1338-palivizumab-rps-update-june-2021.pdf"" target=""_blank"">NHS England</a> and the <a href=""https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/interim-guidance-for-use-of-palivizumab-prophylaxis-to-prevent-hospitalization/"" target=""_blank"">American Academy of Pediatrics</a>. The Committee noted that other agents such as motavizumab and nirsevimab are being investigated for prevention of RSV-related illness and hospitalisation.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that little new evidence had been published since its review of palivizumab in 2009. The Committee noted a recent Cochrane review including five randomised controlled trials that assessed the effects of palivizumab (15 mg/kg once a month for a maximum five doses) compared with placebo, no intervention or standard care for preventing severe RSV infection in children (<a href=""https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013757.pub2/full"" target=""_blank"">Garegnani et al. Cochrane Database Syst Rev. 2021;11(11):CD013757</a>). The Committee noted that the review included 3,343 children aged zero to 24 months of age regardless of RSV infection history and that one study also included hospitalised infants, and that most studies were conducted in children with a high risk of RSV infection (comorbidities eg bronchopulmonary dysplasia and CHD).</p><p class=""ql-indent-1"">1.17.1.<span style=""font-size: 7pt;""> </span>The Committee noted that hospitalisation due to RSV infection at two years&#39; follow‐up was 43 per 1,000 with palivizumab vs 98 per 1,000 with placebo (95% CI: 29 to 62); risk ratio (RR) 0.44, 95% CI 0.30 to 0.64; high certainty evidence). The Committee considered that this provided evidence of a sizeable reduction in hospitalisation in patient groups that align with the target population for New Zealand.</p><p class=""ql-indent-1"">1.17.2.<span style=""font-size: 7pt;""> </span>The Committee noted that all‐cause mortality at two years&#39; follow‐up was 16 per 1,000 with palivizumab vs 23 per 1,000 with placebo (95% CI 10 to 27). The RR (0.69, 95% CI 0.42 to 1.15) was not statistically significant.</p><p class=""ql-indent-1"">1.17.3.<span style=""font-size: 7pt;""> </span>The Committee noted that secondary outcomes included hospitalisation due to respiratory‐related illness, length of hospital stay, number of wheezing days at one-year follow-up, RSV infection at two years follow-up and outcomes relating to ventilation, ICU stays and supplemental oxygen, with most reporting or suggesting some reduction. The Committee considered that the assessment of RSV infection in the community at two years would be hard to quantify; that the number of wheeze days at one year’s follow-up would be of less relevance, and that there was no evidence of an indirect reduction in mortality for RSV patients in the community from a reduction in hospitalisations.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that a randomised, double-blind, placebo-controlled trial of 1,287 children with CHD (previously reviewed by PTAC in 2009) reported that palivizumab recipients had a 45% relative reduction in RSV hospitalizations (<i>P</i>=0.003) (<a href=""https://www.jpeds.com/article/S0022-3476(03)00454-2/fulltext#relatedArticles"" target=""_blank"">Feltes et al. J Pediatr 2003;143:532-40</a>). Members noted that respiratory dysfunction was reported for several months after RSV infection and that patients who had surgery during or immediately after RSV infection had a slight increase in morbidity and a greater need for supplemental oxygen and medication. Members considered RSV infection was known to contribute to surgical delays and complicated diagnoses in children with CHD, however, considered that the impact of palivizumab on cardiac mortality and morbidity was poorly quantified.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee also noted the following updated evidence which was available since its last review of palivizumab in 2009.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://doi.org/10.1002/ppul.20507"" target=""_blank"">Mitchell et al. Pediatr Pulmonol 2006;41:1167-74</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.tandfonline.com/doi/full/10.4161/hv.32082"" target=""_blank"">Ambrose et al. Hum Vaccin Immunother. 2014;10:2785-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://dx.plos.org/10.1371/journal.pone.0100981"" target=""_blank"">Chi et al. PLoS One. 2014;9:e100981</a></p><p class=""ql-indent-1""><span style=""color: rgb(33, 33, 33); font-family: Symbol;"">·</span><span style=""color: rgb(33, 33, 33); font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://onlinelibrary.wiley.com/doi/10.1111/j.1442-200X.2010.03249.x"" target=""_blank"">Kusuda et al. Pediatr Int. 2011;53:368-73</a></p><p><span style=""font-size: 12px;"">1.20.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the new evidence supported earlier findings and that palivizumab still appeared to have low cost-effectiveness. The Committee considered that the evidence for palivizumab prophylaxis in this population supports a reduction in hospitalisation in the target population who are vulnerable and already require a high level of health system engagement and support. The Committee considered that the evidence for most other outcomes from palivizumab prophylaxis was poor, especially for specific population groups (eg infants with immunodeficiency, neuromuscular disorders, or trisomy 21) for whom palivizumab is funded in some jurisdictions but expert opinion about its benefits in these groups is varied. Overall, the Committee considered that the evidence for other potential benefits from palivizumab was of poor quality and weak strength, therefore other benefits to individuals were uncertain and it would not be appropriate to consider long term sequelae associated with palivizumab beyond immediate reduction in hospitalisation.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that although future RSV seasonality was uncertain, in the near future during the COVID-19 pandemic response, a reduction in RSV-related hospitalisations in the target population would be associated with benefits to the New Zealand health system and may help to minimise the risk of hospitalisation during a dual epidemic scenario. However, the Committee considered that longer-term future benefits from palivizumab were uncertain and the longer-term needs of infants at risk of RSV-related hospitalisation and the health system were unclear, due to the uncertain length of the COVID-19 pandemic’s impact on New Zealand and its health system. Therefore, the Committee considered its recommendation for palivizumab should be limited to funding for the next two RSV seasons (2022/2023), with a view to reviewing funding and eligibility criteria two years after this recommendation. The Committee considered this may be difficult to implement within the constraints of the Pharmaceutical Schedule and that consideration of stopping funding after two years would be challenging and likely met with significant resistance.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that palivizumab would not address the disproportionate and inequitable impact of RSV on Māori and Pacific infants. However, the Committee considered targeting Māori and Pacific infants would support equitable health outcomes across infants at high-risk of hospitalisation. The Committee considered it important to avoid disrupting care of premature infants already in hospital (especially those with cardiac disease), to better manage the extra care required for at-risk groups of infants, and to prevent and control intra-hospital infection. <span style=""color: black;"">The Committee considered it appropriate for the Special Authority criteria for palivizumab to specifically target Māori and Pacific infants, given the evidence of higher RSV-hospitalisation rates for these groups. The Committee considered that palivizumab could also be targeted to at-risk premature infants living in areas of high deprivation</span>. The Committee considered that about 900 patients per year would meet the proposed criteria.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that Narayan et al (<a href=""https://www.tandfonline.com/doi/full/10.1080/13696998.2020.1836923"" target=""_blank"">J Med Econ. 2020;23:1640-52</a>) report an average of 3.7 doses of palivizumab used per infant in a cost-effectiveness analysis, however, the Committee considered the likely average number of doses in upcoming years was uncertain given that the future RSV seasonality and impact is unknown. The Committee considered that an initial Special Authority approval duration of six months would facilitate prophylaxis during typical or even slightly longer seasons and be reasonable for fiscal management in uncertain near-future seasons, noting that the 2021 season was unusually short compared to those reported in other countries and given that clinicians would not administer palivizumab unless it was potentially useful and the season was ongoing.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that vial sharing would be expected to occur only at larger treatment centres where large numbers of infants present for prophylaxis and that approximately five infants could receive prophylaxis from three 100mg vials. The Committee noted that the shelf-life of palivizumab is 36 months from the date of manufacture.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that access to clinics for administration would be challenging, requiring family transport to hospital or GP clinics monthly and that this may be significant for infants living in rural area. Overall, the Committee considered that implementation of palivizumab in primary care would be a considerable undertaking with a number of logistic and access issues. The Committee noted that the cost of administration in GP clinics, if not funded, would be passed onto primary care and in turn passed onto family/whānau and would become another access barrier, driving inequity. The Committee also noted the potential challenges of implementation given the pressures from COVID-19 on the healthcare system.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that equitable and effective implementation of palivizumab in the community and in hospitals would be challenging, noting that some patients may commence treatment in hospital while others may be identified in the community. The Committee noted that many premature infants are well known to NICUs and cardiology departments, and therefore are able to be identified, and that learnings from the 2021 NICU-directed implementation could help to inform implementation for 2022/2023. However, the Committee considered that successful implementation would require substantial engagement with relevant clinical teams (eg NICU, cardiology and respiratory teams, infectious diseases) and community health providers (eg Māori health providers, GPs and rural health providers) with resolution of important logistical challenges regarding its distribution, administration and patient identification. The Committee noted that training, support and funding of injection administration would be needed in primary care. Members considered that development of a national registry could help with identification and treatment initiation and considered that Pharmac could engage with the Ministry of Health on this. Overall, the Committee considered an equitable, New Zealand-specific process implementation approach was needed and that engagement with primary care, Māori health providers and relevant hospital clinical teams would help inform this. Members considered that it would be important for Pharmac to monitor and review the implementation of palivizumab in 2021 and over the next two years.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac should inform the Respiratory Advisory Committee and the Immunisation Advisory Committee of the Committee’s recommendation to fund palivizumab prophylaxis for the target population for a period of two seasons (with a view to review two seasons) and could seek further advice from these Advisory Committees about how palivizumab could be effectively and equitably implemented. The Committee considered that Pharmac should seek advice from relevant clinical teams (eg NICU, cardiology and respiratory teams) and community health providers (eg Māori health providers, GPs and rural health providers) to establish an appropriate distribution and implementation approach for palivizumab.</p><p><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Committee considered that the below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for palivizumab if it were to be funded in New Zealand for RSV prophylaxis. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.\xa0</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0P2P000006IiRA&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P0000024yDM"" alt=""image.png""></img></p>', 'fs': '<h2><b style=""font-size: 11px;""><i>Māori impact</i></b></h2><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that respiratory disease inequitably impacts Māori and is one of Pharmac’s Hauora Arotahi (Māori health areas of focus). The Committee noted that RSV-related illness and hospitalisation significantly and disproportionately impacts premature Māori infants in their first year of life, who experience a higher rate of RSV-related hospitalisation compared with European and other (non-Pacific) ethnicities. The Committee noted that Māori infants have a greater relative risk of pre-term birth compared with European infants, and that Māori infants with <span style=""color: rgb(8, 7, 7);"">certain severe congenital heart defects have lower rates of surgical intervention and survival compared with European infants</span>. The Committee considered it important, especially given the disproportionate risk of prematurity and impact of congenital heart defects for Māori, to avoid disrupting care of premature infants already in hospital (especially those with cardiac disease), to better manage the extra care required for at-risk groups of infants, and to prevent and control intra-hospital infection. The Committee noted that the key outcome of benefit from palivizumab was a reduction in hospitalisation and considered that Special Authority criteria for palivizumab should specifically target Māori infants. However, the Committee noted that palivizumab would not address the disproportionate and inequitable impact of RSV on Māori infants. The Committee considered that equitable implementation of palivizumab for RSV prophylaxis would require proactive engagement with relevant parties including Māori healthcare providers and rural healthcare providers, noting that a range of challenges and barriers exist.</p><h2><b style=""font-size: 11px;""><i>Background</i></b></h2><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that an <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008pu58/p000585"" target=""_blank"">application for palivizumab for prevention of serious lower respiratory tract infections (LRTIs) caused by RSV in high-risk infants</a> was reviewed by PTAC and recommended for decline by PTAC at its February 2000, November 2000 meetings. It was formally declined in 2005 by the Pharmac Board.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2009-02.pdf"" target=""_blank"">February 2009</a>, PTAC reviewed a clinician request to allow for a pre-approved Hospital Exceptional Circumstances (HEC) system to allow patients at risk of RSV [infants under 2 years of age with severe chronic lung disease (CLD), with supplemental home oxygen requirements, or in the hospital preparing for discharge with the strong expectation of home oxygen] to access palivizumab. At that time, PTAC recommended it be declined due to the lack of strength and quality of the evidence and poor cost-effectiveness.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in July 2021, in response to the urgent need arising from a major increase in circulating RSV following the COVID-19 lockdown, Pharmac authorised DHBs to purchase palivizumab outside of the Pharmaceutical Schedule for high-risk patients that met certain criteria during the 2021 RSV outbreak. The target population was restricted to manage supply issues at the time whilst enabling access for high-risk patients. In <a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-09-20-palivizumab/"" target=""_blank"">September 2021</a>, Pharmac authorised widening of access for the 2021 RSV season to the intended, limited high-risk patient population.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pharmac received a funding application for palivizumab for RSV prophylaxis from a clinician in July 2021 and was seeking the Committee’s advice on this application in the context of the COVID-19 pandemic.</p><h2><b style=""font-size: 11px;""><i>Discussion</i></b></h2><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that RSV is the dominant respiratory virus accounting in New Zealand for about half of all cases of bronchiolitis, an acute respiratory infection, in infants and young children (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805750/"" target=""_blank"">Prasad et al. Epidemiol Infect. 2019; 147: e246</a>; <a href=""https://publications.aap.org/pediatrics/article-lookup/doi/10.1542/peds.2018-2308"" target=""_blank"">Alansari et al. Pediatrics. 2019;143:e20182308</a>). The Committee noted that RSV infects a large proportion of children who are less than one year of age, including many under three months or six months of age, and considered this was important, given the exponential lung development that occurs in the first year of life. The Committee noted that RSV cases present with symptoms of respiratory distress (predominantly wheeze), that the virus affects more boys than girls, and that RSV-related illness is treated with supportive care.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that RSV disproportionately impacts indigenous populations worldwide. Respiratory disease is known to have an inequitable impact on Māori and is one of Pharmac’s <a href=""https://pharmac.govt.nz/te-tiriti-o-waitangi/hauora-arotahi-maori-health-areas-of-focus/"" target=""_blank"">Hauora Arotahi</a><span style=""color: rgb(51, 51, 51);""> </span>(Māori health areas of focus). The Committee noted that RSV-related illness and hospitalisation disproportionately impacts premature Māori infants in their first year of life<span style=""color: black;"">.</span> The Committee noted that RSV-related <span style=""color: black;"">hospitalisation was higher in Māori children [rate ratio (RR) 4.0, 95% CI: 3.4 to 4.7] compared with European or other ethnicities </span><span style=""color: rgb(33, 33, 33);"">(</span><a href=""https://doi.org/10.1097/INF.0000000000002681"" target=""_blank"">Prasad et al. Pediatr Infect Dis J. 2020;39:e176-e182</a><span style=""color: rgb(33, 33, 33);"">). </span><span style=""color: black;"">The Committee was made aware of evidence of infants admitted to a New Zealand paediatric intensive care unit with bronchiolitis from 1991 to 1994; members considered this suggested that Māori infants with RSV are disproportionally represented in these admissions. Members noted however that there was no difference based on ethnicity for patients who required respiratory support (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/8649668/"" target=""_blank"">Gavin et al. N Z Med J. 1996;109:137-9</a><span style=""color: rgb(33, 33, 33);"">). </span>The Committee noted that <span style=""color: rgb(8, 7, 7);"">Māori women had a greater relative risk of having extremely or very preterm infants than European women, and that the relative risk of neonatal death or post-neonatal death was higher in Māori women than European women (</span><a href=""https://doi.org/10.1002/ijgo.13855"" target=""_blank"">Edmonds et al. Int J Gynaecol Obstet. 2021;155:239-46</a><span style=""color: rgb(8, 7, 7);"">). The Committee noted that, although Māori infants may not have higher rates of CHD than non-Māori, there is evidence that Māori infants with certain severe congenital heart defects have lower rates of surgical intervention and lower survival rates compared with European infants (</span><a href=""https://adc.bmj.com/lookup/pmidlookup?view=long&amp;pmid=30824490"" target=""_blank"">Cloete et al. Arch Dis Child. 2019;104:857-62</a><span style=""color: rgb(8, 7, 7);"">). </span></p><p><span style=""font-size: 12px;"">1.8</span><i style=""font-size: 12px;"">.</i><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that RSV also disproportionately impacts premature Pacific infants in their first year of life. The rate of RSV-related <span style=""color: black;"">hospitalisation was also higher in Pacific children (RR 2.9, 95% CI: 2.5 to 3.4) compared with European or other ethnicities </span><span style=""color: rgb(33, 33, 33);"">(</span><a href=""https://doi.org/10.1097/INF.0000000000002681"" target=""_blank"">Prasad et al. 2020</a><span style=""color: rgb(33, 33, 33);"">)</span><span style=""color: black;"">. </span>Members noted that, like Māori infants, Pacific infants and Indian infants are overrepresented in the incidence of pre-term births <span style=""color: rgb(8, 7, 7);"">(</span><a href=""https://doi.org/10.1002/ijgo.13855"" target=""_blank"">Edmonds et al. 2021)</a>. <span style=""color: rgb(33, 33, 33);"">The </span><span style=""color: black;"">Committee </span>noted that no New Zealand-specific data were available for the rates of RSV-related hospitalisation in Indian infants. The Committee noted that living in an area of low <span style=""color: black;"">socio-economic status\xa0(SES) (deprivation index 8 to 10) </span>independently increased the risk of an RSV-associated hospitalisation in children<span style=""font-size: 10pt;""> </span>(RR 1.3, 95% CI 1.0 to 1.6) <span style=""color: rgb(33, 33, 33);"">(</span><a href=""https://doi.org/10.1097/INF.0000000000002681"" target=""_blank"">Prasad et al. 2020</a><span style=""color: rgb(33, 33, 33);"">)</span>. Given the evidenced increase in risk of RSV-associated hospitalisation for infants in areas of high deprivation, the Committee considered it could be appropriate to target these infants for funded treatment.<span style=""color: rgb(33, 33, 33);""> </span></p><p><span style=""font-size: 12px;"">1.9</span><i style=""font-size: 12px;"">.</i><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that premature infants, infants with lung disease, and infants with CHD are the patient groups most at risk of RSV-related hospitalisation. Members noted there is ongoing debate regarding whether infants who are immunocompromised, have neuromuscular disorders, have trisomy 21, or require long-term ventilation have the same elevated risk of RSV-related hospitalisation.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that hospitalisation itself adversely affects normal family/whānau functioning and that hospitalisation for RSV further impacts family/whānau where children are usually transferred to large treatment centres (eg Auckland’s Starship Hospital) for care. The Committee noted the family/whānau impact of hospitalisation for RSV was reported in a study of caregivers of pre-term US infants hospitalised with RSV, who experienced stress, poor health and productivity loss at discharge, and were emotionally impacted, had disruption of family routine, financial concerns and medical concerns continue after discharge (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31007050/"" target=""_blank"">Pokrzywinski et al. Clin Pediatr (Phila). 2019;58:837-50</a>).</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that RSV typically circulates annually in the winter season from May to October in New Zealand and that in Auckland, laboratory-confirmed RSV cases peak at about 50 cases per week, contributing substantially to the number of hospitalisations for acute bronchiolitis (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805750/"" target=""_blank"">Prasad et al. 2019</a>). The Committee noted that the authors of this Auckland-based study reported that half of RSV-related hospitalisations were in children under six months and that that hospitalisation due to RSV was 30 times as likely in children less than three months of age compared with children aged two to five years. The Committee noted that from 2012 to 2015, 5,309 overnight hospitalisations (median 2 days duration) were reported for acute respiratory infection among children aged under five years, with 433 (8.2%) admitted to intensive care units (ICU). The Committee considered that this reflected the substantial health resource needed to care for young children hospitalised with RSV and the high rate of paediatric ICU (PICU) admissions that result. However, the Committee considered that further health resources are required for infection prevention and control measures, as RSV can spread rapidly within hospitals, and noted that unwell infants including those at high risk of RSV-related hospitalisation already require substantial care and engagement with neonatal facilities in hospital.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that mortality from RSV is low in New Zealand, noting a recent study reported the rate of death among RSV-positive children was 0.18% (n=3), compared with the rate of all-cause mortality among all patients admitted overnight for acute respiratory infection (0.4%, n=19) (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805750/"" target=""_blank"">Prasad et al. 2019</a>). However, the Committee noted that some infants hospitalised with RSV are assumed to experience an increased risk of death, ranging from 3.72% to 4% for CHD and CLD patients, respectively, and 0.43% for premature babies (less than 32 weeks gestational age) without CHD and CLD (<a href=""https://pubmed.ncbi.nlm.nih.gov/19049692/"" target=""_blank"">Wang et al, Health Technol Assess. 2008</a>). The Committee noted the evidence for a reduction in mortality following hospitalisation in infants hospitalised for RSV who received palivizumab compared with those who received placebo, no intervention, or standard care (two-year all-cause mortality relative risk [RR] 0.69, 95% CI 0.42 to 1.15; <a href=""https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013757.pub2/full"" target=""_blank"">Garegnani et al. Cochrane Database Syst Rev. 2021;11(11):CD013757</a>). The Committee was made aware of weak evidence for hospital mortality of children with congenital heart disease up to 12 months of age (0.56% in 2012 to 2014 vs 1.93% in 2014 to 2016, <i>P</i> = 0.051; <a href=""http://hdl.handle.net/2027.42/144272"" target=""_blank"">Walpert et al. Congenit Heart Dis. 2018;13:428-31</a>). Members considered that hospitalisation in PICU may be associated with increased all-cause mortality and that bronchiolitis could contribute to overall mortality. On balance, the Committee considered the difference in the mortality risk for hospitalised infants with RSV compared with infants in the community with RSV was very low.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that a very small minority of infants and children can have virus-associated encephalopathy and cardiomyopathy and some may have mild respiratory damage after RSV infection, lasting three to four months. Members considered that two or three children with RSV per year (especially those with pre-existing lung pathology) develop long-term lung pathology from ventilation treatment. The Committee considered that ongoing effects such as wheeze, subsequent bronchiolitis, and an increased risk of RSV infection generally last up to one year and would not require significant intervention or treatment. The Committee considered that the association between RSV infection and asthma post-RSV was uncertain and that a possible link was likely to be complicated by other factors.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the public health measures, border closures and restrictions used in response to the COVID-19 pandemic resulted in a lack of circulating RSV and no noteworthy 2020 RSV season. The Committee noted that alleviation of these measures and the lack of previous exposure to RSV for infants led to a larger and longer atypical 2021 season of RSV circulation which peaked at about 1,000 laboratory-confirmed RSV cases per week in Auckland (compared to previous peak of about 50 cases per week). The Committee noted that 2021 season put enormous pressure on secondary care, impacting on hospitals and ICU beds, caused staff and family sickness, led to elective surgery cancellations and intra-hospital spread. The Committee noted that primary care including GP and nurse teams managed the vast majority of RSV cases in 2021 which impacted the ability of primary care to provide usual care (eg resulting in deferral of routine smears and diabetes reviews).</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the COVID-19 response applies similar pressures to both primary and secondary care services, with limited capacity for ICU care of infants with RSV requiring hospitalisation. The Committee considered that an increase in morbidity and mortality in some populations would be expected if an RSV season overlapped with COVID-19 circulation (eg leading to dual RSV and COVID-19 infections in critically ill inpatients) and that premature infants may be at greater risk if hospitals are at capacity treating COVID-19 cases. The Committee considered that future RSV seasonality is uncertain but, given the atypical RSV seasons overseas, that it was possible New Zealand would also experience an atypical future season or out-of-season surge with greater impact than typical RSV seasons. The Committee considered that significant health system resource would be needed to manage an atypical RSV season in the context of the COVID-19 pandemic response and that reducing hospitalisation was a key area of need for the health system.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that palivizumab is a humanised IgG1 monoclonal antibody that is Medsafe- approved for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease. The Committee noted that palivizumab is administered in a dose of 15 mg/kg intramuscularly and should be given monthly during anticipated periods of RSV risk in the community. The Committee noted that palivizumab has been recommended for RSV prophylaxis in some international jurisdictions (eg UK, Canada, Australia), in paediatric clinical guidelines (eg UK and USA) and considered that the jurisdictions reporting better cost-effectiveness with palivizumab had targeted access to populations most at risk of RSV-related hospitalisation. The Committee noted that palivizumab had recently been recommended for at-risk preterm infants in the context of COVID-19 by <a href=""https://www.england.nhs.uk/wp-content/uploads/2020/10/C1338-palivizumab-rps-update-june-2021.pdf"" target=""_blank"">NHS England</a> and the <a href=""https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/interim-guidance-for-use-of-palivizumab-prophylaxis-to-prevent-hospitalization/"" target=""_blank"">American Academy of Pediatrics</a>. The Committee noted that other agents such as motavizumab and nirsevimab are being investigated for prevention of RSV-related illness and hospitalisation.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that little new evidence had been published since its review of palivizumab in 2009. The Committee noted a recent Cochrane review including five randomised controlled trials that assessed the effects of palivizumab (15 mg/kg once a month for a maximum five doses) compared with placebo, no intervention or standard care for preventing severe RSV infection in children (<a href=""https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013757.pub2/full"" target=""_blank"">Garegnani et al. Cochrane Database Syst Rev. 2021;11(11):CD013757</a>). The Committee noted that the review included 3,343 children aged zero to 24 months of age regardless of RSV infection history and that one study also included hospitalised infants, and that most studies were conducted in children with a high risk of RSV infection (comorbidities eg bronchopulmonary dysplasia and CHD).</p><p class=""ql-indent-1"">1.17.1.<span style=""font-size: 7pt;""> </span>The Committee noted that hospitalisation due to RSV infection at two years&#39; follow‐up was 43 per 1,000 with palivizumab vs 98 per 1,000 with placebo (95% CI: 29 to 62); risk ratio (RR) 0.44, 95% CI 0.30 to 0.64; high certainty evidence). The Committee considered that this provided evidence of a sizeable reduction in hospitalisation in patient groups that align with the target population for New Zealand.</p><p class=""ql-indent-1"">1.17.2.<span style=""font-size: 7pt;""> </span>The Committee noted that all‐cause mortality at two years&#39; follow‐up was 16 per 1,000 with palivizumab vs 23 per 1,000 with placebo (95% CI 10 to 27). The RR (0.69, 95% CI 0.42 to 1.15) was not statistically significant.</p><p class=""ql-indent-1"">1.17.3.<span style=""font-size: 7pt;""> </span>The Committee noted that secondary outcomes included hospitalisation due to respiratory‐related illness, length of hospital stay, number of wheezing days at one-year follow-up, RSV infection at two years follow-up and outcomes relating to ventilation, ICU stays and supplemental oxygen, with most reporting or suggesting some reduction. The Committee considered that the assessment of RSV infection in the community at two years would be hard to quantify; that the number of wheeze days at one year’s follow-up would be of less relevance, and that there was no evidence of an indirect reduction in mortality for RSV patients in the community from a reduction in hospitalisations.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that a randomised, double-blind, placebo-controlled trial of 1,287 children with CHD (previously reviewed by PTAC in 2009) reported that palivizumab recipients had a 45% relative reduction in RSV hospitalizations (<i>P</i>=0.003) (<a href=""https://www.jpeds.com/article/S0022-3476(03)00454-2/fulltext#relatedArticles"" target=""_blank"">Feltes et al. J Pediatr 2003;143:532-40</a>). Members noted that respiratory dysfunction was reported for several months after RSV infection and that patients who had surgery during or immediately after RSV infection had a slight increase in morbidity and a greater need for supplemental oxygen and medication. Members considered RSV infection was known to contribute to surgical delays and complicated diagnoses in children with CHD, however, considered that the impact of palivizumab on cardiac mortality and morbidity was poorly quantified.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee also noted the following updated evidence which was available since its last review of palivizumab in 2009.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://doi.org/10.1002/ppul.20507"" target=""_blank"">Mitchell et al. Pediatr Pulmonol 2006;41:1167-74</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.tandfonline.com/doi/full/10.4161/hv.32082"" target=""_blank"">Ambrose et al. Hum Vaccin Immunother. 2014;10:2785-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://dx.plos.org/10.1371/journal.pone.0100981"" target=""_blank"">Chi et al. PLoS One. 2014;9:e100981</a></p><p class=""ql-indent-1""><span style=""color: rgb(33, 33, 33); font-family: Symbol;"">·</span><span style=""color: rgb(33, 33, 33); font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://onlinelibrary.wiley.com/doi/10.1111/j.1442-200X.2010.03249.x"" target=""_blank"">Kusuda et al. Pediatr Int. 2011;53:368-73</a></p><p><span style=""font-size: 12px;"">1.20.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the new evidence supported earlier findings and that palivizumab still appeared to have low cost-effectiveness. The Committee considered that the evidence for palivizumab prophylaxis in this population supports a reduction in hospitalisation in the target population who are vulnerable and already require a high level of health system engagement and support. The Committee considered that the evidence for most other outcomes from palivizumab prophylaxis was poor, especially for specific population groups (eg infants with immunodeficiency, neuromuscular disorders, or trisomy 21) for whom palivizumab is funded in some jurisdictions but expert opinion about its benefits in these groups is varied. Overall, the Committee considered that the evidence for other potential benefits from palivizumab was of poor quality and weak strength, therefore other benefits to individuals were uncertain and it would not be appropriate to consider long term sequelae associated with palivizumab beyond immediate reduction in hospitalisation.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that although future RSV seasonality was uncertain, in the near future during the COVID-19 pandemic response, a reduction in RSV-related hospitalisations in the target population would be associated with benefits to the New Zealand health system and may help to minimise the risk of hospitalisation during a dual epidemic scenario. However, the Committee considered that longer-term future benefits from palivizumab were uncertain and the longer-term needs of infants at risk of RSV-related hospitalisation and the health system were unclear, due to the uncertain length of the COVID-19 pandemic’s impact on New Zealand and its health system. Therefore, the Committee considered its recommendation for palivizumab should be limited to funding for the next two RSV seasons (2022/2023), with a view to reviewing funding and eligibility criteria two years after this recommendation. The Committee considered this may be difficult to implement within the constraints of the Pharmaceutical Schedule and that consideration of stopping funding after two years would be challenging and likely met with significant resistance.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that palivizumab would not address the disproportionate and inequitable impact of RSV on Māori and Pacific infants. However, the Committee considered targeting Māori and Pacific infants would support equitable health outcomes across infants at high-risk of hospitalisation. The Committee considered it important to avoid disrupting care of premature infants already in hospital (especially those with cardiac disease), to better manage the extra care required for at-risk groups of infants, and to prevent and control intra-hospital infection. <span style=""color: black;"">The Committee considered it appropriate for the Special Authority criteria for palivizumab to specifically target Māori and Pacific infants, given the evidence of higher RSV-hospitalisation rates for these groups. The Committee considered that palivizumab could also be targeted to at-risk premature infants living in areas of high deprivation</span>. The Committee considered that about 900 patients per year would meet the proposed criteria.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that Narayan et al (<a href=""https://www.tandfonline.com/doi/full/10.1080/13696998.2020.1836923"" target=""_blank"">J Med Econ. 2020;23:1640-52</a>) report an average of 3.7 doses of palivizumab used per infant in a cost-effectiveness analysis, however, the Committee considered the likely average number of doses in upcoming years was uncertain given that the future RSV seasonality and impact is unknown. The Committee considered that an initial Special Authority approval duration of six months would facilitate prophylaxis during typical or even slightly longer seasons and be reasonable for fiscal management in uncertain near-future seasons, noting that the 2021 season was unusually short compared to those reported in other countries and given that clinicians would not administer palivizumab unless it was potentially useful and the season was ongoing.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that vial sharing would be expected to occur only at larger treatment centres where large numbers of infants present for prophylaxis and that approximately five infants could receive prophylaxis from three 100mg vials. The Committee noted that the shelf-life of palivizumab is 36 months from the date of manufacture.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that access to clinics for administration would be challenging, requiring family transport to hospital or GP clinics monthly and that this may be significant for infants living in rural area. Overall, the Committee considered that implementation of palivizumab in primary care would be a considerable undertaking with a number of logistic and access issues. The Committee noted that the cost of administration in GP clinics, if not funded, would be passed onto primary care and in turn passed onto family/whānau and would become another access barrier, driving inequity. The Committee also noted the potential challenges of implementation given the pressures from COVID-19 on the healthcare system.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that equitable and effective implementation of palivizumab in the community and in hospitals would be challenging, noting that some patients may commence treatment in hospital while others may be identified in the community. The Committee noted that many premature infants are well known to NICUs and cardiology departments, and therefore are able to be identified, and that learnings from the 2021 NICU-directed implementation could help to inform implementation for 2022/2023. However, the Committee considered that successful implementation would require substantial engagement with relevant clinical teams (eg NICU, cardiology and respiratory teams, infectious diseases) and community health providers (eg Māori health providers, GPs and rural health providers) with resolution of important logistical challenges regarding its distribution, administration and patient identification. The Committee noted that training, support and funding of injection administration would be needed in primary care. Members considered that development of a national registry could help with identification and treatment initiation and considered that Pharmac could engage with the Ministry of Health on this. Overall, the Committee considered an equitable, New Zealand-specific process implementation approach was needed and that engagement with primary care, Māori health providers and relevant hospital clinical teams would help inform this. Members considered that it would be important for Pharmac to monitor and review the implementation of palivizumab in 2021 and over the next two years.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac should inform the Respiratory Advisory Committee and the Immunisation Advisory Committee of the Committee’s recommendation to fund palivizumab prophylaxis for the target population for a period of two seasons (with a view to review two seasons) and could seek further advice from these Advisory Committees about how palivizumab could be effectively and equitably implemented. The Committee considered that Pharmac should seek advice from relevant clinical teams (eg NICU, cardiology and respiratory teams) and community health providers (eg Māori health providers, GPs and rural health providers) to establish an appropriate distribution and implementation approach for palivizumab.</p><p><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Committee considered that the below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for palivizumab if it were to be funded in New Zealand for RSV prophylaxis. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.\xa0</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0P2P000006IiRA&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P0000024yDM"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee reviewed a clinician application for palivizumab for respiratory syncytial virus (RSV) prophylaxis in children under the age of 12 months who are at high risk of RSV-related hospitalisation.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pharmac sought advice on this application in the context of:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The atypical RSV seasons arising from the COVID-19 pandemic and restrictions</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The impact of COVID-19 on the healthcare system and intensive care units in particular</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The disproportionate effect of RSV on Māori and Pacific infants</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>A recent clinician application for a Pharmaceutical Schedule listing for palivizumab (Synagis) for RSV.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>PTAC’s prior review of palivizumab for the prophylactic treatment of RSV in pre-term infants.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee reviewed a clinician application for palivizumab for respiratory syncytial virus (RSV) prophylaxis in children under the age of 12 months who are at high risk of RSV-related hospitalisation.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pharmac sought advice on this application in the context of:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The atypical RSV seasons arising from the COVID-19 pandemic and restrictions</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The impact of COVID-19 on the healthcare system and intensive care units in particular</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The disproportionate effect of RSV on Māori and Pacific infants</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>A recent clinician application for a Pharmaceutical Schedule listing for palivizumab (Synagis) for RSV.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>PTAC’s prior review of palivizumab for the prophylactic treatment of RSV in pre-term infants.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2022', 'fs': 'May 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2022.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2022.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006IiRAUA0'}, 'Id': 'a0P2P000006IiRAUA0', 'Event_Date__c': '2022-05-13', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2022.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'May 2022', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that palivizumab be funded for the next two RSV seasons (2022/2023), with a view to reviewing funding and eligibility criteria following the 2023 RSV season (i.e. at two years after this recommendation), for RSV prophylaxis of children under the age of 12 months who are at high risk of developing RSV disease, with a <b>high priority</b>, subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><b style=""font-size: 11px; color: rgb(51, 51, 51);"">PALIVIZUMAB – RSV PROPHYLAXIS FOR THE 2022/2023 RSV SEASONS, IN THE CONTEXT OF COVID-19</b></p><p class=""ql-indent-1""><b style=""font-size: 11px; color: rgb(51, 51, 51);"">Initial application </b><span style=""font-size: 11px; color: rgb(51, 51, 51);"">only from a paediatrician. Approvals valid for 6 months.</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">1.\xa0\xa0\xa0\xa0Infant was born in the last 12 months; and</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.\xa0\xa0\xa0\xa0Any of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.1. Patient was born at less than 28 weeks gestation; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2. Both:</span></p><p class=""ql-indent-2""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2.1. Patient was born at less than 32 weeks gestation; and</span></p><p class=""ql-indent-2""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2.2. Either: </span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2.2.1. Patient has chronic lung disease; or</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.2.2.2. Patient is Māori or any Pacific ethnicity; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3. Both:</span></p><p class=""ql-indent-2""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.1. Patient has haemodynamically significant heart disease; and</span></p><p class=""ql-indent-2""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2. Any of the following:</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2.1. Patient has unoperated simple congenital heart disease with significant left to right shunt (see note a); or</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2.2. Patient has unoperated or surgically palliated complex congenital heart disease; or</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2.3. Patient has severe pulmonary hypertension (see note b); or</span></p><p class=""ql-indent-3""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">2.3.2.4. Patient has moderate or severe LV failure (see note c)</span></p><p><span style=""font-size: 11px;"">\t</span><b style=""font-size: 11px; color: rgb(51, 51, 51);"">Note</b><span style=""font-size: 11px; color: rgb(51, 51, 51);"">:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">a)\xa0\xa0\xa0\xa0Patient requires/will require heart failure medication, and/or patient has significant pulmonary hypertension, and/or patient will require surgical palliation/definitive repair within the next 3 months</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">b)\xa0\xa0\xa0\xa0Mean pulmonary artery pressure more than 45 mmHg</span></p><p class=""ql-indent-1""><span style=""font-size: 11px; color: rgb(51, 51, 51);"">c)\xa0\xa0\xa0\xa0LV Ejection Fraction less than 40%</span></p><p class=""ql-indent-1""><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee considered that:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>RSV significantly and disproportionately impacts premature infants who are Māori, Pacific, or living in areas with low socio-economic status (deprivation index 8-10) in their first year of life</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The seasonal characteristics of RSV are highly uncertain in the next two years in the context of the COVID-19 pandemic and an atypical season with greater impact than normal RSV seasons cannot be ruled out</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence for palivizumab prophylaxis in this population supports a reduction in hospitalisation in the target population who are vulnerable and already require a high level of health system engagement and support</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In the context of the COVID-19 pandemic, reducing hospitalisations in this target population would be associated with benefits to the health system, given the expected burdens on DHB hospitals and ICUs</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence for other potential benefits (eg reductions in mortality or respiratory sequelae) from palivizumab is of poor quality and weak strength therefore other benefits to individuals remain unquantified</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Equitable and effective implementation of palivizumab prophylaxis will require substantial engagement with the relevant clinical teams and community health providers, and resolution of important logistical challenges regarding its distribution.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac should inform the Respiratory Advisory Committee and the Immunisation Advisory Committee of the Committee’s recommendation to fund palivizumab prophylaxis for the target population for the next two RSV seasons and suggested staff seek advice from these Advisory Committees about how palivizumab access could be effectively and equitably implemented.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac could seek advice from relevant clinical teams [eg neonatal intensive care units (NICU), cardiology and respiratory teams, infectious diseases] and community health providers (eg Māori health providers, GPs and rural health providers) to establish an appropriate distribution and implementation approach for the provision of palivizumab prophylaxis for the next two RSV seasons.</p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee reviewed a clinician application for palivizumab for respiratory syncytial virus (RSV) prophylaxis in children under the age of 12 months who are at high risk of RSV-related hospitalisation.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pharmac sought advice on this application in the context of:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The atypical RSV seasons arising from the COVID-19 pandemic and restrictions</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The impact of COVID-19 on the healthcare system and intensive care units in particular</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The disproportionate effect of RSV on Māori and Pacific infants</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>A recent clinician application for a Pharmaceutical Schedule listing for palivizumab (Synagis) for RSV.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>PTAC’s prior review of palivizumab for the prophylactic treatment of RSV in pre-term infants.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'Published_Discussion__c': '<h2><b style=""font-size: 11px;""><i>Māori impact</i></b></h2><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that respiratory disease inequitably impacts Māori and is one of Pharmac’s Hauora Arotahi (Māori health areas of focus). The Committee noted that RSV-related illness and hospitalisation significantly and disproportionately impacts premature Māori infants in their first year of life, who experience a higher rate of RSV-related hospitalisation compared with European and other (non-Pacific) ethnicities. The Committee noted that Māori infants have a greater relative risk of pre-term birth compared with European infants, and that Māori infants with <span style=""color: rgb(8, 7, 7);"">certain severe congenital heart defects have lower rates of surgical intervention and survival compared with European infants</span>. The Committee considered it important, especially given the disproportionate risk of prematurity and impact of congenital heart defects for Māori, to avoid disrupting care of premature infants already in hospital (especially those with cardiac disease), to better manage the extra care required for at-risk groups of infants, and to prevent and control intra-hospital infection. The Committee noted that the key outcome of benefit from palivizumab was a reduction in hospitalisation and considered that Special Authority criteria for palivizumab should specifically target Māori infants. However, the Committee noted that palivizumab would not address the disproportionate and inequitable impact of RSV on Māori infants. The Committee considered that equitable implementation of palivizumab for RSV prophylaxis would require proactive engagement with relevant parties including Māori healthcare providers and rural healthcare providers, noting that a range of challenges and barriers exist.</p><h2><b style=""font-size: 11px;""><i>Background</i></b></h2><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that an <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008pu58/p000585"" target=""_blank"">application for palivizumab for prevention of serious lower respiratory tract infections (LRTIs) caused by RSV in high-risk infants</a> was reviewed by PTAC and recommended for decline by PTAC at its February 2000, November 2000 meetings. It was formally declined in 2005 by the Pharmac Board.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2009-02.pdf"" target=""_blank"">February 2009</a>, PTAC reviewed a clinician request to allow for a pre-approved Hospital Exceptional Circumstances (HEC) system to allow patients at risk of RSV [infants under 2 years of age with severe chronic lung disease (CLD), with supplemental home oxygen requirements, or in the hospital preparing for discharge with the strong expectation of home oxygen] to access palivizumab. At that time, PTAC recommended it be declined due to the lack of strength and quality of the evidence and poor cost-effectiveness.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in July 2021, in response to the urgent need arising from a major increase in circulating RSV following the COVID-19 lockdown, Pharmac authorised DHBs to purchase palivizumab outside of the Pharmaceutical Schedule for high-risk patients that met certain criteria during the 2021 RSV outbreak. The target population was restricted to manage supply issues at the time whilst enabling access for high-risk patients. In <a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-09-20-palivizumab/"" target=""_blank"">September 2021</a>, Pharmac authorised widening of access for the 2021 RSV season to the intended, limited high-risk patient population.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pharmac received a funding application for palivizumab for RSV prophylaxis from a clinician in July 2021 and was seeking the Committee’s advice on this application in the context of the COVID-19 pandemic.</p><h2><b style=""font-size: 11px;""><i>Discussion</i></b></h2><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that RSV is the dominant respiratory virus accounting in New Zealand for about half of all cases of bronchiolitis, an acute respiratory infection, in infants and young children (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805750/"" target=""_blank"">Prasad et al. Epidemiol Infect. 2019; 147: e246</a>; <a href=""https://publications.aap.org/pediatrics/article-lookup/doi/10.1542/peds.2018-2308"" target=""_blank"">Alansari et al. Pediatrics. 2019;143:e20182308</a>). The Committee noted that RSV infects a large proportion of children who are less than one year of age, including many under three months or six months of age, and considered this was important, given the exponential lung development that occurs in the first year of life. The Committee noted that RSV cases present with symptoms of respiratory distress (predominantly wheeze), that the virus affects more boys than girls, and that RSV-related illness is treated with supportive care.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that RSV disproportionately impacts indigenous populations worldwide. Respiratory disease is known to have an inequitable impact on Māori and is one of Pharmac’s <a href=""https://pharmac.govt.nz/te-tiriti-o-waitangi/hauora-arotahi-maori-health-areas-of-focus/"" target=""_blank"">Hauora Arotahi</a><span style=""color: rgb(51, 51, 51);""> </span>(Māori health areas of focus). The Committee noted that RSV-related illness and hospitalisation disproportionately impacts premature Māori infants in their first year of life<span style=""color: black;"">.</span> The Committee noted that RSV-related <span style=""color: black;"">hospitalisation was higher in Māori children [rate ratio (RR) 4.0, 95% CI: 3.4 to 4.7] compared with European or other ethnicities </span><span style=""color: rgb(33, 33, 33);"">(</span><a href=""https://doi.org/10.1097/INF.0000000000002681"" target=""_blank"">Prasad et al. Pediatr Infect Dis J. 2020;39:e176-e182</a><span style=""color: rgb(33, 33, 33);"">). </span><span style=""color: black;"">The Committee was made aware of evidence of infants admitted to a New Zealand paediatric intensive care unit with bronchiolitis from 1991 to 1994; members considered this suggested that Māori infants with RSV are disproportionally represented in these admissions. Members noted however that there was no difference based on ethnicity for patients who required respiratory support (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/8649668/"" target=""_blank"">Gavin et al. N Z Med J. 1996;109:137-9</a><span style=""color: rgb(33, 33, 33);"">). </span>The Committee noted that <span style=""color: rgb(8, 7, 7);"">Māori women had a greater relative risk of having extremely or very preterm infants than European women, and that the relative risk of neonatal death or post-neonatal death was higher in Māori women than European women (</span><a href=""https://doi.org/10.1002/ijgo.13855"" target=""_blank"">Edmonds et al. Int J Gynaecol Obstet. 2021;155:239-46</a><span style=""color: rgb(8, 7, 7);"">). The Committee noted that, although Māori infants may not have higher rates of CHD than non-Māori, there is evidence that Māori infants with certain severe congenital heart defects have lower rates of surgical intervention and lower survival rates compared with European infants (</span><a href=""https://adc.bmj.com/lookup/pmidlookup?view=long&amp;pmid=30824490"" target=""_blank"">Cloete et al. Arch Dis Child. 2019;104:857-62</a><span style=""color: rgb(8, 7, 7);"">). </span></p><p><span style=""font-size: 12px;"">1.8</span><i style=""font-size: 12px;"">.</i><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that RSV also disproportionately impacts premature Pacific infants in their first year of life. The rate of RSV-related <span style=""color: black;"">hospitalisation was also higher in Pacific children (RR 2.9, 95% CI: 2.5 to 3.4) compared with European or other ethnicities </span><span style=""color: rgb(33, 33, 33);"">(</span><a href=""https://doi.org/10.1097/INF.0000000000002681"" target=""_blank"">Prasad et al. 2020</a><span style=""color: rgb(33, 33, 33);"">)</span><span style=""color: black;"">. </span>Members noted that, like Māori infants, Pacific infants and Indian infants are overrepresented in the incidence of pre-term births <span style=""color: rgb(8, 7, 7);"">(</span><a href=""https://doi.org/10.1002/ijgo.13855"" target=""_blank"">Edmonds et al. 2021)</a>. <span style=""color: rgb(33, 33, 33);"">The </span><span style=""color: black;"">Committee </span>noted that no New Zealand-specific data were available for the rates of RSV-related hospitalisation in Indian infants. The Committee noted that living in an area of low <span style=""color: black;"">socio-economic status\xa0(SES) (deprivation index 8 to 10) </span>independently increased the risk of an RSV-associated hospitalisation in children<span style=""font-size: 10pt;""> </span>(RR 1.3, 95% CI 1.0 to 1.6) <span style=""color: rgb(33, 33, 33);"">(</span><a href=""https://doi.org/10.1097/INF.0000000000002681"" target=""_blank"">Prasad et al. 2020</a><span style=""color: rgb(33, 33, 33);"">)</span>. Given the evidenced increase in risk of RSV-associated hospitalisation for infants in areas of high deprivation, the Committee considered it could be appropriate to target these infants for funded treatment.<span style=""color: rgb(33, 33, 33);""> </span></p><p><span style=""font-size: 12px;"">1.9</span><i style=""font-size: 12px;"">.</i><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that premature infants, infants with lung disease, and infants with CHD are the patient groups most at risk of RSV-related hospitalisation. Members noted there is ongoing debate regarding whether infants who are immunocompromised, have neuromuscular disorders, have trisomy 21, or require long-term ventilation have the same elevated risk of RSV-related hospitalisation.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that hospitalisation itself adversely affects normal family/whānau functioning and that hospitalisation for RSV further impacts family/whānau where children are usually transferred to large treatment centres (eg Auckland’s Starship Hospital) for care. The Committee noted the family/whānau impact of hospitalisation for RSV was reported in a study of caregivers of pre-term US infants hospitalised with RSV, who experienced stress, poor health and productivity loss at discharge, and were emotionally impacted, had disruption of family routine, financial concerns and medical concerns continue after discharge (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31007050/"" target=""_blank"">Pokrzywinski et al. Clin Pediatr (Phila). 2019;58:837-50</a>).</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that RSV typically circulates annually in the winter season from May to October in New Zealand and that in Auckland, laboratory-confirmed RSV cases peak at about 50 cases per week, contributing substantially to the number of hospitalisations for acute bronchiolitis (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805750/"" target=""_blank"">Prasad et al. 2019</a>). The Committee noted that the authors of this Auckland-based study reported that half of RSV-related hospitalisations were in children under six months and that that hospitalisation due to RSV was 30 times as likely in children less than three months of age compared with children aged two to five years. The Committee noted that from 2012 to 2015, 5,309 overnight hospitalisations (median 2 days duration) were reported for acute respiratory infection among children aged under five years, with 433 (8.2%) admitted to intensive care units (ICU). The Committee considered that this reflected the substantial health resource needed to care for young children hospitalised with RSV and the high rate of paediatric ICU (PICU) admissions that result. However, the Committee considered that further health resources are required for infection prevention and control measures, as RSV can spread rapidly within hospitals, and noted that unwell infants including those at high risk of RSV-related hospitalisation already require substantial care and engagement with neonatal facilities in hospital.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that mortality from RSV is low in New Zealand, noting a recent study reported the rate of death among RSV-positive children was 0.18% (n=3), compared with the rate of all-cause mortality among all patients admitted overnight for acute respiratory infection (0.4%, n=19) (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805750/"" target=""_blank"">Prasad et al. 2019</a>). However, the Committee noted that some infants hospitalised with RSV are assumed to experience an increased risk of death, ranging from 3.72% to 4% for CHD and CLD patients, respectively, and 0.43% for premature babies (less than 32 weeks gestational age) without CHD and CLD (<a href=""https://pubmed.ncbi.nlm.nih.gov/19049692/"" target=""_blank"">Wang et al, Health Technol Assess. 2008</a>). The Committee noted the evidence for a reduction in mortality following hospitalisation in infants hospitalised for RSV who received palivizumab compared with those who received placebo, no intervention, or standard care (two-year all-cause mortality relative risk [RR] 0.69, 95% CI 0.42 to 1.15; <a href=""https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013757.pub2/full"" target=""_blank"">Garegnani et al. Cochrane Database Syst Rev. 2021;11(11):CD013757</a>). The Committee was made aware of weak evidence for hospital mortality of children with congenital heart disease up to 12 months of age (0.56% in 2012 to 2014 vs 1.93% in 2014 to 2016, <i>P</i> = 0.051; <a href=""http://hdl.handle.net/2027.42/144272"" target=""_blank"">Walpert et al. Congenit Heart Dis. 2018;13:428-31</a>). Members considered that hospitalisation in PICU may be associated with increased all-cause mortality and that bronchiolitis could contribute to overall mortality. On balance, the Committee considered the difference in the mortality risk for hospitalised infants with RSV compared with infants in the community with RSV was very low.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that a very small minority of infants and children can have virus-associated encephalopathy and cardiomyopathy and some may have mild respiratory damage after RSV infection, lasting three to four months. Members considered that two or three children with RSV per year (especially those with pre-existing lung pathology) develop long-term lung pathology from ventilation treatment. The Committee considered that ongoing effects such as wheeze, subsequent bronchiolitis, and an increased risk of RSV infection generally last up to one year and would not require significant intervention or treatment. The Committee considered that the association between RSV infection and asthma post-RSV was uncertain and that a possible link was likely to be complicated by other factors.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the public health measures, border closures and restrictions used in response to the COVID-19 pandemic resulted in a lack of circulating RSV and no noteworthy 2020 RSV season. The Committee noted that alleviation of these measures and the lack of previous exposure to RSV for infants led to a larger and longer atypical 2021 season of RSV circulation which peaked at about 1,000 laboratory-confirmed RSV cases per week in Auckland (compared to previous peak of about 50 cases per week). The Committee noted that 2021 season put enormous pressure on secondary care, impacting on hospitals and ICU beds, caused staff and family sickness, led to elective surgery cancellations and intra-hospital spread. The Committee noted that primary care including GP and nurse teams managed the vast majority of RSV cases in 2021 which impacted the ability of primary care to provide usual care (eg resulting in deferral of routine smears and diabetes reviews).</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the COVID-19 response applies similar pressures to both primary and secondary care services, with limited capacity for ICU care of infants with RSV requiring hospitalisation. The Committee considered that an increase in morbidity and mortality in some populations would be expected if an RSV season overlapped with COVID-19 circulation (eg leading to dual RSV and COVID-19 infections in critically ill inpatients) and that premature infants may be at greater risk if hospitals are at capacity treating COVID-19 cases. The Committee considered that future RSV seasonality is uncertain but, given the atypical RSV seasons overseas, that it was possible New Zealand would also experience an atypical future season or out-of-season surge with greater impact than typical RSV seasons. The Committee considered that significant health system resource would be needed to manage an atypical RSV season in the context of the COVID-19 pandemic response and that reducing hospitalisation was a key area of need for the health system.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that palivizumab is a humanised IgG1 monoclonal antibody that is Medsafe- approved for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease. The Committee noted that palivizumab is administered in a dose of 15 mg/kg intramuscularly and should be given monthly during anticipated periods of RSV risk in the community. The Committee noted that palivizumab has been recommended for RSV prophylaxis in some international jurisdictions (eg UK, Canada, Australia), in paediatric clinical guidelines (eg UK and USA) and considered that the jurisdictions reporting better cost-effectiveness with palivizumab had targeted access to populations most at risk of RSV-related hospitalisation. The Committee noted that palivizumab had recently been recommended for at-risk preterm infants in the context of COVID-19 by <a href=""https://www.england.nhs.uk/wp-content/uploads/2020/10/C1338-palivizumab-rps-update-june-2021.pdf"" target=""_blank"">NHS England</a> and the <a href=""https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/interim-guidance-for-use-of-palivizumab-prophylaxis-to-prevent-hospitalization/"" target=""_blank"">American Academy of Pediatrics</a>. The Committee noted that other agents such as motavizumab and nirsevimab are being investigated for prevention of RSV-related illness and hospitalisation.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that little new evidence had been published since its review of palivizumab in 2009. The Committee noted a recent Cochrane review including five randomised controlled trials that assessed the effects of palivizumab (15 mg/kg once a month for a maximum five doses) compared with placebo, no intervention or standard care for preventing severe RSV infection in children (<a href=""https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013757.pub2/full"" target=""_blank"">Garegnani et al. Cochrane Database Syst Rev. 2021;11(11):CD013757</a>). The Committee noted that the review included 3,343 children aged zero to 24 months of age regardless of RSV infection history and that one study also included hospitalised infants, and that most studies were conducted in children with a high risk of RSV infection (comorbidities eg bronchopulmonary dysplasia and CHD).</p><p class=""ql-indent-1"">1.17.1.<span style=""font-size: 7pt;""> </span>The Committee noted that hospitalisation due to RSV infection at two years&#39; follow‐up was 43 per 1,000 with palivizumab vs 98 per 1,000 with placebo (95% CI: 29 to 62); risk ratio (RR) 0.44, 95% CI 0.30 to 0.64; high certainty evidence). The Committee considered that this provided evidence of a sizeable reduction in hospitalisation in patient groups that align with the target population for New Zealand.</p><p class=""ql-indent-1"">1.17.2.<span style=""font-size: 7pt;""> </span>The Committee noted that all‐cause mortality at two years&#39; follow‐up was 16 per 1,000 with palivizumab vs 23 per 1,000 with placebo (95% CI 10 to 27). The RR (0.69, 95% CI 0.42 to 1.15) was not statistically significant.</p><p class=""ql-indent-1"">1.17.3.<span style=""font-size: 7pt;""> </span>The Committee noted that secondary outcomes included hospitalisation due to respiratory‐related illness, length of hospital stay, number of wheezing days at one-year follow-up, RSV infection at two years follow-up and outcomes relating to ventilation, ICU stays and supplemental oxygen, with most reporting or suggesting some reduction. The Committee considered that the assessment of RSV infection in the community at two years would be hard to quantify; that the number of wheeze days at one year’s follow-up would be of less relevance, and that there was no evidence of an indirect reduction in mortality for RSV patients in the community from a reduction in hospitalisations.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members noted that a randomised, double-blind, placebo-controlled trial of 1,287 children with CHD (previously reviewed by PTAC in 2009) reported that palivizumab recipients had a 45% relative reduction in RSV hospitalizations (<i>P</i>=0.003) (<a href=""https://www.jpeds.com/article/S0022-3476(03)00454-2/fulltext#relatedArticles"" target=""_blank"">Feltes et al. J Pediatr 2003;143:532-40</a>). Members noted that respiratory dysfunction was reported for several months after RSV infection and that patients who had surgery during or immediately after RSV infection had a slight increase in morbidity and a greater need for supplemental oxygen and medication. Members considered RSV infection was known to contribute to surgical delays and complicated diagnoses in children with CHD, however, considered that the impact of palivizumab on cardiac mortality and morbidity was poorly quantified.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee also noted the following updated evidence which was available since its last review of palivizumab in 2009.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://doi.org/10.1002/ppul.20507"" target=""_blank"">Mitchell et al. Pediatr Pulmonol 2006;41:1167-74</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.tandfonline.com/doi/full/10.4161/hv.32082"" target=""_blank"">Ambrose et al. Hum Vaccin Immunother. 2014;10:2785-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://dx.plos.org/10.1371/journal.pone.0100981"" target=""_blank"">Chi et al. PLoS One. 2014;9:e100981</a></p><p class=""ql-indent-1""><span style=""color: rgb(33, 33, 33); font-family: Symbol;"">·</span><span style=""color: rgb(33, 33, 33); font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://onlinelibrary.wiley.com/doi/10.1111/j.1442-200X.2010.03249.x"" target=""_blank"">Kusuda et al. Pediatr Int. 2011;53:368-73</a></p><p><span style=""font-size: 12px;"">1.20.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the new evidence supported earlier findings and that palivizumab still appeared to have low cost-effectiveness. The Committee considered that the evidence for palivizumab prophylaxis in this population supports a reduction in hospitalisation in the target population who are vulnerable and already require a high level of health system engagement and support. The Committee considered that the evidence for most other outcomes from palivizumab prophylaxis was poor, especially for specific population groups (eg infants with immunodeficiency, neuromuscular disorders, or trisomy 21) for whom palivizumab is funded in some jurisdictions but expert opinion about its benefits in these groups is varied. Overall, the Committee considered that the evidence for other potential benefits from palivizumab was of poor quality and weak strength, therefore other benefits to individuals were uncertain and it would not be appropriate to consider long term sequelae associated with palivizumab beyond immediate reduction in hospitalisation.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that although future RSV seasonality was uncertain, in the near future during the COVID-19 pandemic response, a reduction in RSV-related hospitalisations in the target population would be associated with benefits to the New Zealand health system and may help to minimise the risk of hospitalisation during a dual epidemic scenario. However, the Committee considered that longer-term future benefits from palivizumab were uncertain and the longer-term needs of infants at risk of RSV-related hospitalisation and the health system were unclear, due to the uncertain length of the COVID-19 pandemic’s impact on New Zealand and its health system. Therefore, the Committee considered its recommendation for palivizumab should be limited to funding for the next two RSV seasons (2022/2023), with a view to reviewing funding and eligibility criteria two years after this recommendation. The Committee considered this may be difficult to implement within the constraints of the Pharmaceutical Schedule and that consideration of stopping funding after two years would be challenging and likely met with significant resistance.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that palivizumab would not address the disproportionate and inequitable impact of RSV on Māori and Pacific infants. However, the Committee considered targeting Māori and Pacific infants would support equitable health outcomes across infants at high-risk of hospitalisation. The Committee considered it important to avoid disrupting care of premature infants already in hospital (especially those with cardiac disease), to better manage the extra care required for at-risk groups of infants, and to prevent and control intra-hospital infection. <span style=""color: black;"">The Committee considered it appropriate for the Special Authority criteria for palivizumab to specifically target Māori and Pacific infants, given the evidence of higher RSV-hospitalisation rates for these groups. The Committee considered that palivizumab could also be targeted to at-risk premature infants living in areas of high deprivation</span>. The Committee considered that about 900 patients per year would meet the proposed criteria.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that Narayan et al (<a href=""https://www.tandfonline.com/doi/full/10.1080/13696998.2020.1836923"" target=""_blank"">J Med Econ. 2020;23:1640-52</a>) report an average of 3.7 doses of palivizumab used per infant in a cost-effectiveness analysis, however, the Committee considered the likely average number of doses in upcoming years was uncertain given that the future RSV seasonality and impact is unknown. The Committee considered that an initial Special Authority approval duration of six months would facilitate prophylaxis during typical or even slightly longer seasons and be reasonable for fiscal management in uncertain near-future seasons, noting that the 2021 season was unusually short compared to those reported in other countries and given that clinicians would not administer palivizumab unless it was potentially useful and the season was ongoing.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that vial sharing would be expected to occur only at larger treatment centres where large numbers of infants present for prophylaxis and that approximately five infants could receive prophylaxis from three 100mg vials. The Committee noted that the shelf-life of palivizumab is 36 months from the date of manufacture.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that access to clinics for administration would be challenging, requiring family transport to hospital or GP clinics monthly and that this may be significant for infants living in rural area. Overall, the Committee considered that implementation of palivizumab in primary care would be a considerable undertaking with a number of logistic and access issues. The Committee noted that the cost of administration in GP clinics, if not funded, would be passed onto primary care and in turn passed onto family/whānau and would become another access barrier, driving inequity. The Committee also noted the potential challenges of implementation given the pressures from COVID-19 on the healthcare system.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that equitable and effective implementation of palivizumab in the community and in hospitals would be challenging, noting that some patients may commence treatment in hospital while others may be identified in the community. The Committee noted that many premature infants are well known to NICUs and cardiology departments, and therefore are able to be identified, and that learnings from the 2021 NICU-directed implementation could help to inform implementation for 2022/2023. However, the Committee considered that successful implementation would require substantial engagement with relevant clinical teams (eg NICU, cardiology and respiratory teams, infectious diseases) and community health providers (eg Māori health providers, GPs and rural health providers) with resolution of important logistical challenges regarding its distribution, administration and patient identification. The Committee noted that training, support and funding of injection administration would be needed in primary care. Members considered that development of a national registry could help with identification and treatment initiation and considered that Pharmac could engage with the Ministry of Health on this. Overall, the Committee considered an equitable, New Zealand-specific process implementation approach was needed and that engagement with primary care, Māori health providers and relevant hospital clinical teams would help inform this. Members considered that it would be important for Pharmac to monitor and review the implementation of palivizumab in 2021 and over the next two years.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac should inform the Respiratory Advisory Committee and the Immunisation Advisory Committee of the Committee’s recommendation to fund palivizumab prophylaxis for the target population for a period of two seasons (with a view to review two seasons) and could seek further advice from these Advisory Committees about how palivizumab could be effectively and equitably implemented. The Committee considered that Pharmac should seek advice from relevant clinical teams (eg NICU, cardiology and respiratory teams) and community health providers (eg Māori health providers, GPs and rural health providers) to establish an appropriate distribution and implementation approach for palivizumab.</p><p><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Committee considered that the below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for palivizumab if it were to be funded in New Zealand for RSV prophylaxis. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.\xa0</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0P2P000006IiRA&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P0000024yDM"" alt=""image.png""></img></p>', 'Status_History__c': 'a132P000000DklzQAC'}, 'change': None}]",Jul 2021,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2022', 'fs': 'Feb 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006IiR8UAK'}, 'Id': 'a0P2P000006IiR8UAK', 'Event_Date__c': '2022-02-22', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2022', 'Status_History__c': 'a132P000000DYUuQAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006IiR9UAK'}, 'Id': 'a0P2P000006IiR9UAK', 'Event_Date__c': '2022-03-01', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Mar 2022', 'Status_History__c': 'a132P000000DZZ2QAO'}, 'change': None}]",Feb 2022,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,,,False,False
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': '<p><span style=""color: rgb(51, 51, 51); font-size: 16px;"">To enable potential funding as early as possible (from 1 June 2022), we undertook a shortened, targeted consultation with clinicians and DHBs. We circulated a consultation letter in early May to relevant clinicians and stakeholders who are involved in the management and/or treatment of infants at high risk of RSV-related illness and complications. We specifically sought feedback on implementation considerations and the proposed eligibility criteria. </span><span style=""color: rgb(51, 51, 51); font-size: 16px; background-color: rgb(255, 255, 255);"">A summary of the feedback we received and our responses can be found in the Pharmac notification.</span></p>', 'fs': '<p><span style=""color: rgb(51, 51, 51); font-size: 16px;"">To enable potential funding as early as possible (from 1 June 2022), we undertook a shortened, targeted consultation with clinicians and DHBs. We circulated a consultation letter in early May to relevant clinicians and stakeholders who are involved in the management and/or treatment of infants at high risk of RSV-related illness and complications. We specifically sought feedback on implementation considerations and the proposed eligibility criteria. </span><span style=""color: rgb(51, 51, 51); font-size: 16px; background-color: rgb(255, 255, 255);"">A summary of the feedback we received and our responses can be found in the Pharmac notification.</span></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-05-16-palivizumab/"" target=""_blank"">Notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-05-16-palivizumab/"" target=""_blank"">Notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'May 2022', 'fs': 'May 2022', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006IiRBUA0'}, 'Id': 'a0P2P000006IiRBUA0', 'Event_Date__c': '2022-05-19', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-05-16-palivizumab/"" target=""_blank"">Notification</a></p>', 'Summary__c': '<p><span style=""color: rgb(51, 51, 51); font-size: 16px;"">To enable potential funding as early as possible (from 1 June 2022), we undertook a shortened, targeted consultation with clinicians and DHBs. We circulated a consultation letter in early May to relevant clinicians and stakeholders who are involved in the management and/or treatment of infants at high risk of RSV-related illness and complications. We specifically sought feedback on implementation considerations and the proposed eligibility criteria. </span><span style=""color: rgb(51, 51, 51); font-size: 16px; background-color: rgb(255, 255, 255);"">A summary of the feedback we received and our responses can be found in the Pharmac notification.</span></p>', 'Formatted_Date__c': 'May 2022', 'Status_History__c': 'a132P000000DlhIQAS'}, 'change': None}]",May 2022,False,True
